Peapack-Gladstone Financial Corp’s Charles River Laboratories CRL Stock Holding History

Peapack-Gladstone Financial Corp’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-655	Closed	-$270K	–	690
2021 Q3	$270K	Sell	655 -128	-16%	-$53.2K	0.01%	561
2021 Q2	$290K	Buy	783 +3	+0.4%	+$1K	0.01%	523
2021 Q1	$226K	Sell	780 -31	-4%	-$8.62K	0.01%	543
2020 Q4	$203K	Sell	811 -124	-13%	-$29.5K	0.01%	409
2020 Q3	$212K	Buy	+935	New	+$194K	0.01%	355

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Peapack-Gladstone Financial Corp's CRL Position: Q4 2021 in Review

Peapack-Gladstone Financial Corp sold out of Charles River Laboratories (CRL) in Q4 2021, closing a stake of 655 shares — an estimated $270K sold.

Peapack-Gladstone Financial Corp first reported a position in CRL in Q3 2020 and held it in 5 quarters. The position peaked at $290K in Q2 2021. 707 funds tracked by Wall St. Rank hold CRL as of Q4 2021.

Peapack-Gladstone Financial Corp reported no remaining Charles River Laboratories position as of Q4 2021 after selling out during the quarter.
Peapack-Gladstone Financial Corp sold 655 Charles River Laboratories shares in Q4 2021, an estimated $270K.
Peapack-Gladstone Financial Corp first reported a position in Charles River Laboratories in Q3 2020 and held it in 5 quarters.
Peapack-Gladstone Financial Corp's Charles River Laboratories position peaked at $290K in Q2 2021.
707 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2021.

Based on Peapack-Gladstone Financial Corp's 13F filing for Q4 2021, filed 15 Feb 2022.